期刊文献+

自体外周血干细胞加激活骨髓联合移植治疗T细胞淋巴瘤的诱导移植物抗宿主病 被引量:2

原文传递
导出
摘要 目的研究自体造血干细胞(APBSC)加激活骨髓(ABM)联合移植治疗淋巴瘤过程中ABM诱导移植物抗宿主病(GVHD)的作用。方法一例T免疫母细胞非霍奇金淋巴瘤(NHL)患者行APBSC+ABM联合移植治疗,观察皮疹、腹泻及黄疽的发生。结果皮肤出现I-Ⅱ度GVHD改变,无腹泻及黄疸,已无瘤生存13年。结论APBSC加ABM联合移植能诱导GVHD,并获得长期无病生存的疗效。
出处 《白血病.淋巴瘤》 CAS 2011年第9期566-567,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献3

二级参考文献12

  • 1刘启发,周淑芸.白细胞介素2激活的骨髓对自身骨髓中白血病细胞的净化作用[J].中国实验血液学杂志,1996,4(4):405-407. 被引量:2
  • 2张伯龙,黄文荣,达万明,张占强,姚善谦,高春记,韩晓萍,吴晓雄,王全顺,于力,张苗,靳海杰.双次自体造血干细胞移植治疗恶性血液病的临床分析[J].中华医学杂志,2002,82(2):123-126. 被引量:3
  • 3高春记,楼方定,姚善谦,刘海川,朱军,周绮,孟凡义,韩晓萍,王小沛.自体造血干细胞移植后造血功能重建的影响因素[J].中华血液学杂志,1994,15(10):538-539. 被引量:2
  • 4李晓诗.白细胞介素-2在骨髓移植中的应用[J].国外医学(输血及血液学分册),1995,18(2):97-99. 被引量:6
  • 5Weiden PL, Sullivan KM, Fluornoy N, et al. Antileukemic effect of graft versus host disease. Contribution to improved survival after allogeneic marrow transplantation [ J ]. N Engl J Med, 1980, 304 ( 25 ) :1529- 1533.
  • 6Jones RJ, Vogelsang GB, Hess AD, et al. Induction of graft-versushost disease after autologous bone marrow transplantation[J]. Lancet,1989,1(8641) :754 - 757.
  • 7Kennedy MJ, Vogelsang GB, Beveridge RA, et ol. Phase I trial intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer[J]. J Clin Oncol, 1993,11 (3) :478 - 484.
  • 8Weiden PL, Sullivan KM, Fluornoy N, et al. Antileukemic effect of graft-versts-host disease in human recipients of allogeneic-marrow grafts[J]. N Engl J Med, 1979,300(19) : 1068 - 1073.
  • 9Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants[J]. Science,2002,295(5562) :2097 - 2100.
  • 10Carella AM, Gaozza E, Congiu A, et al. Cyclosporine-induced graftversts-host disease after autologous bone marrow transplantation in hematological malignancies[J]. Ann Hematol, 1991,62(5) : 156- 159.

共引文献13

同被引文献32

  • 1周生余,石远凯,何小慧,张频,董梅,黄鼎智,杨建良,张长弓,刘鹏,杨晟,冯奉仪.DICE方案治疗复发或耐药中高度恶性非霍奇金淋巴瘤[J].癌症,2005,24(4):465-469. 被引量:29
  • 2王潞,叶晓兵,吴跃文,杨志敏.DICE方案治疗难治性或复发性NHL[J].实用全科医学,2005,3(5):397-398. 被引量:3
  • 3Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumor. Lyon:IARC Press, 200 I.
  • 4Multani P, ,White CA, Grillo-Lopez A. Non-Hodgkin's lymphoma: review of conventional treatmentsl. Curr Pharm Biotechnol, 2001 , 2: 279-291.
  • 5Gisselbreeht C, Mounier N. Improing second-line therapy in aggressive non-Hodgkin :s lymphoma. Semin Oncol, 2004,31 : 12-16.
  • 6Kimby E~ Brandt-L, Nygren P, et al. A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncol, 2001, 40:198-212.
  • 7Hagemeister FB, Donato M. Ifosfamide - based chemotherapy regimens in treatment of lymphoma : the M. D. Anderson experience. Eur J Haematol Suppl, 2001, 64:8-13.
  • 8Haim N, Rosenblatt E, Wollner M, et al. Salvage therapy for non- Hodgin's lymphoma with a combination of dexamethasone, etopo-side, ifosfamide and cisp latin. Cancer Chemother Pharmaco|, 1992, 30: 243 -244.
  • 9Coleman M, Leonard J, ShusterMW, et al. DICE ( dexamethasone, if- osfamide, cisp latin, etoposide ) ~nfusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). Eur J Haematol Suppl, 2001, 64: 41- 45.
  • 10Morton L,Wang S,Devesa S. Lymphoma incidence patterns by WHO subtype in the United States,1992-2001[J].Blood,2006.265-276.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部